Keybank National Association OH Grows Holdings in Cencora, Inc. (NYSE:COR)

Keybank National Association OH raised its position in Cencora, Inc. (NYSE:COR) by 2.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,901 shares of the company’s stock after buying an additional 195 shares during the period. Keybank National Association OH’s holdings in Cencora were worth $1,775,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Cornerstone Investment Partners LLC lifted its stake in shares of Cencora by 9.8% in the fourth quarter. Cornerstone Investment Partners LLC now owns 344,011 shares of the company’s stock worth $77,292,000 after acquiring an additional 30,646 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its holdings in Cencora by 23.3% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 1,192 shares of the company’s stock worth $268,000 after purchasing an additional 225 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Cencora by 6.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,027,871 shares of the company’s stock valued at $230,942,000 after purchasing an additional 66,328 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its stake in shares of Cencora by 0.7% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 52,968 shares of the company’s stock valued at $11,901,000 after buying an additional 343 shares during the last quarter. Finally, Fidelis Capital Partners LLC grew its position in shares of Cencora by 69.9% during the fourth quarter. Fidelis Capital Partners LLC now owns 2,368 shares of the company’s stock worth $532,000 after buying an additional 974 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

COR has been the topic of several recent analyst reports. StockNews.com cut shares of Cencora from a “buy” rating to a “hold” rating in a report on Tuesday. JPMorgan Chase & Co. upped their target price on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Robert W. Baird lifted their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Wells Fargo & Company boosted their price objective on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. Finally, Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the transaction, the chief executive officer now owns 51,070 shares in the company, valued at $13,022,850. This represents a 8.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,648 shares of company stock valued at $2,862,342. Corporate insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $253.51 on Friday. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The stock has a fifty day moving average price of $243.79 and a 200 day moving average price of $238.29. The company has a market cap of $49.16 billion, a P/E ratio of 36.06, a PEG ratio of 1.31 and a beta of 0.49.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.